THE EXPERIENCE OF USE OF PREDILUTIONARY ON-LINE HEMODIAFILTRATION IN PATIENTS WITH END STAGE RENAL DISEASE
https://doi.org/10.24884/1561-6274-2008-12-4-36-44
Abstract
THE AIM of the investigation: on the basis of the investigation of the dynamics of clinical and laboratory data to give a complex evaluation of the effectiveness of predilutionary hemofiltration in ESRD. PATIENTS AND METHODS. The total number of investigated patients was 86. After randomization, 46 patients were picked, and divided into two groups: main group (25 patients) instead of hemodyalisis procedure had an predilutionary on-line hemofiltration of the mean of 12,5 hours per week. The control group (21 patient) had chronic hemodyalisis of the same duration. The observation on the main (HDF) and control (CG) groups was made during 1,5 month – 6 weeks – 20 sessions of RRT. The most often cause for the development of the terminal stage of HRF, in the main group patients with was chronic glomerulonephritis (74%), chronic pielonephritis (4%), renal polycystosis (8%), diabetes (4%), system vasculitis (8%); in the control group patients – glomerulonephritis (71%), chronic pielonephritis (14%), renal polycystosis (10%), diabetes (6%). RESULTS. The positive effect of predilutionary on-line hemofiltration on the data that characterizes the hemodynamic stability and dialysis doze (p<0,001), the increase of LPLD was noted (p<0,004), also was noted the decrease in the level of total homocystein (p<0,001) and C-reactive protein (p<0,002). The reliable decrease in the dilatational level of phosphate (p<0,0015) and parathyroid hormone (p<0,003) was noted, and also a valuable increase in the red blood values. A decrease of the total protein level and plasma albumin in patients receiving HDF therapy was observed. CONCLUSION. The use of predilutionary on-line hemofiltration during the 1,5 month has a complex positive effect on the majority of the values of the substance exchange in the patients with terminal renal failure.
About the Authors
A. N. Vasiliev
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова
Russian Federation
Russian Federation
N. Ya. Gubar
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова
Russian Federation
Russian Federation
A. V. Smirnov
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова
Russian Federation
Russian Federation
E. D. Suglobova
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова
Russian Federation
Russian Federation
References
1. Lowrie EG, Lew NL. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15 (5): 458-482
2. Phelan P, O’Kelly P, Walshe J et al. The importance of serum albumin and phosphorous as predictors of mortality in ESRD patients. Ren Fail2008; 30 (4): 423-429
3. Cruz D, de Cal M, Ronco C. Oxidative stress and anemia in chronic hemodialysis: the promise of bioreactive membranes. Contrib Nephrol 2008; 161: 89-98
4. Ostermann M. Cardiac arrests in hemodialysis patients: An ongoing challenge. Kidney Int 2008; 73 (4): 907-908
5. Barri Y. Hypertension and kidney disease: a deadly connection. Curr Hypertens Rep 2008; 10 (1): 39-45
6. London G, Marchais S, Guerin A et al. Arterial hypertension, chronic renal insufficiency and dialysis. Nephrol Ther 2007; 3 [Suppl 3]: S156-161
7. Culleton BF, Wilson PW. Cardiovascular disease: risk factors, secular trends, and therapeutic guidelines. J Am Soc Nephrol 1998; 9 [Suppl 12]: S5-S15
8. Kunz K, Petitjean P, Lisri M et al. Cardiovascular morbidity and endothelial dysfunction in chronic HD patients: is homocysteine the missing link? Nephrol Dial Transpl 1999; 14 (8): 1934-1942
9. Bostom A.G, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52 (1): 10-20
10. Chauveau P, Chadefaux B, Coude M et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993; 43 [Suppl 41]: 72-77
11. Haas T, Hillton D, Dongardy G. Phosphate kinetics in dialysis patients. Nephrol Dial Transpl 1991; 6 [Suppl 2]: 108-113
12. McCarley PB, Arjomand M. Mineral and bone disorders in patients on dialysis: physiology and clinical consequences. Nephrol Nurs J 2008; 35 (1): 59-64
13. Akgul A, Bilgic A, Sezer S et al. Low total plasma homocysteine level in relation to malnutrition, inflammation, and outcome in hemodialysis patients. J Ren Nutr 2008; 18 (4): 338-346
14. Warren DJ, Otieno LS. Carpal tunnel syndrome in patients on intermittent hemodialysis. Postgrad Med J 1975; 51 (597): 450-452
15. Eckard KU. Anaemia correction – does the mode of dialysis matter. Nephrol Dial Transpl 2000; 15(9): 1278-1280
16. Chanard J, Brunois IP, Melin JP et al. Long-term result of dialysis therapy with a highly permeable membrane. Artif Organs 1982; 6 (3): 261-266
17. Leypoldt JK, Schmidt B, Gurland HJ. Net ultrafiltration may not eliminate backfiltration during hemodialysis with highly permeable membranes. Artif Organs 1991; 15 (3): 164-170
18. Henderson LW. The beginning of Hemofiltration. Contribution to Nephrology 1982; 32: 1-20
19. Lysaght MJ. The History of Hemofiltration. Hemofiltration. Springer-Verlag, 1986; 1-17
20. Canaud B, Bosc JY, Leray-Moragues H et al. On-line hemodiafiltration. Safety and effcacy in long-term clinical practice. Nephrol Dial Transplant 2000; 15 [Suppl 1]: 60-67
21. Жлоба АА, Блашко ЭЛ. Определение общего гомоцистеина в плазме крови методом обращеннофазной жидкостной хроматографии с использованием колонок С 8 и С 18. Уч записки СПбГМУ им акад И. П. Павлова 2004; 11 (2): 20-25
22. Ware JE, Snow KK, Kosinski M et al. SF"36 Health Survey. Manual and interpretation guide.The Health Institute, New England Medical Center. Boston, 1993; 19-22
23. Rahman M, Fu P, Sehgal AR et al. Interdialytic weight gain, compliance with dialysis regimen, and age are independent predictors of blood pressure in hemodialysis patients. Am J Kidney Dis 2000; 35 (2): 257-265
24. Rocco MV, Yan G, Heyka RJ et al. Risk factors for hypertension in chronic hemodialysis patients: baseline data from the HEMO study. Am J Nephrol 2001; 21 (4): 280-288
25. Смирнов АВ, Рыков ВГ, Суглобова ЕД. Артериальная гипертензия, как фактор риска повышенной летальности у больных, получающих лечение методом хронического гемодиализа, и подходы к ее коррекции. Нефрология 2003; 7 (3): 7-13
26. Kooman J, Basci A, Pizzarelli F et al. EBPG guideline on hemodynamic instability. Nephrol Dial Transplant 2007; 22 [Suppl 2]: ii22-44
27. Donauer J, Schweiger C, Rumberger B et al. Reduction of hypotensive side effects during online-hemodiafiltration and low temperature hemodialysis. Nephrol Dial Transplant 2003; 18 (6): 1616-1622
28. Santoro A, Mancini E, Canova C et al. Thermal balance in convective therapies. Nephrol Dial Transplant 2003; 18 [Suppl 7]: vii41-vii45
29. Butkevich A, Phillips RA, Sheinart KF et al. The effects of various definitions of dipping and daytime and night-time on characterization of 24h profiles of blood pressure. Blood Press. Monit 2000; 5: 19-22
30. Ahlman J. Quality of life of the dialysis patient in Replacement of renal function by dialysis. In: Jacobs C, Kjellstrand CM, Koch KM, eds. Kluwer, Dordecht/Boston/London, 1996: 460-477
31. Щербак ИГ. Биологическая химия.Изд-во СПбГМУ, СПб, 2005: 350-369
32. Basile C. The effect of convection on the nutritional status of haemodialysis patients. Nephrol Dial Transplant 2003; 18 [Suppl 7]: vii46-vii49
33. Desmeules S, Levesque R, Jaussent I et al. Creatinine index and lean body mass are excellent predictors of long-term survival in hemodiafiltration patients. Nephrol Dial Transplant 2004; 19 (5): 1182-1189
34. Kaysen GA. Role of inflammation and its treatment in ESRD patients. Blood Purif 2002; 20 (1): 70-80
35. Назаров ПГ. Реактанты острой фазы воспаления. Наука, СПб., 2001; 125-133
36. Cotter D, Zhang Y, Thamer M et al. The effect of epoetin dose on hematocrit. Kidney Int 2008; 73 (3): 347-53
37. Macdougall IC, Padhi D, Jang G. Pharmacology of darbepoetin alfa. Nephrol Dial Transplant 2007; 22 [Suppl 4]: iv2-iv9
38. Ермоленко ВМ, Иващенко МА. Уремия и эритропоэтин. Медицина, М., 1999; 86-89
39. Константинов ЮВ, Гуревич КЯ, Абдурахимов СМ. Оценка адекватности хронического диализа. Санкт-Петербург, 1999. 1-29
40. Pertosa G, Grandaliano G, Gesualdo L et al. Clinical relevance of cytokines production in hemodialysis. Kidney Int 2000; 58 [Suppl 76]: S104-111
41. Lin CL, Huang CC, Yu CC et al. Improved iron utilization and reduced erythropoetin resistance by on-line hemodiafiltration. Blood Purif 2002; 20 (4): 349-356
42. Kaysen GA. The microinflammatory state in uremia: Causes and potential consequences. J Am Soc Nephrol 2001; 12: 1549-1555
43. Meytes D, Bodin E, Ma A et al. Effect of parathyreoid hormone on erythropoesis. J Clin Invest 1981; 67: 1263-1269
44. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium-phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis1998; 31 (4): 607-617
Review
For citations:
Vasiliev A.N., Gubar N.Ya., Smirnov A.V., Suglobova E.D. THE EXPERIENCE OF USE OF PREDILUTIONARY ON-LINE HEMODIAFILTRATION IN PATIENTS WITH END STAGE RENAL DISEASE. Nephrology (Saint-Petersburg). 2008;12(4):36-44. (In Russ.) https://doi.org/10.24884/1561-6274-2008-12-4-36-44
Views:
283
Email this article 